SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-009555
Filing Date
2020-08-06
Accepted
2020-08-06 11:17:00
Documents
58
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20200630x10q.htm   iXBRL 10-Q 1903508
2 EX-31.1 adap-20200630xex31d1.htm EX-31.1 9802
3 EX-31.2 adap-20200630xex31d2.htm EX-31.2 10545
4 EX-32.1 adap-20200630xex32d1.htm EX-32.1 6111
5 EX-32.2 adap-20200630xex32d2.htm EX-32.2 6093
  Complete submission text file 0001558370-20-009555.txt   5229161

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20200630.xsd EX-101.SCH 33135
7 EX-101.CAL adap-20200630_cal.xml EX-101.CAL 43326
8 EX-101.DEF adap-20200630_def.xml EX-101.DEF 86480
9 EX-101.LAB adap-20200630_lab.xml EX-101.LAB 305032
10 EX-101.PRE adap-20200630_pre.xml EX-101.PRE 209550
11 EXTRACTED XBRL INSTANCE DOCUMENT adap-20200630x10q_htm.xml XML 717866
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 201080521
SIC: 2836 Biological Products, (No Diagnostic Substances)